anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Most women with breast cancer are prone to postoperative sleep disturbances (POSD). Little is known about the differences between sevoflurane and propofol combined with dexmedetomidine on POSD in the same context. We investigated the effect of intra-operative sevoflurane or propofol combined with intravenous dexmedetomidine on the incidence of POSD and postoperative sleep structures.
METHODS: A monocentric, randomized-controlled, double-blind trial. Female patients undergoing radical surgery for breast cancer were randomly assigned to receive sevoflurane and placebo, sevoflurane and dexmedetomidine, propofol and placebo, or propofol and dexmedetomidine. Dexmedetomidine was administered at 1.0 μg kg-1 infusion 15 min before induction, then infused at 0.4 μg kg-1 h-1 until the surgical drain started to be placed. The primary outcome was the incidence of POSD within the postoperative first three days (defined as an Athens Insomnia Scale score ≥ 6 points on at least one day of postoperative first three days). The secondary outcome was the duration of sleep structures, collected from the Fitbit Charge 2® smart bracelet (Fitbit, Inc., San Francisco, CA, USA).
RESULTS: There were 188 women analyzed with the modified intention-to-treat method. The incidences of POSD in the dexmedetomidine and placebo groups were similar (p = 0.649). In the sevoflurane sedation strategy, dexmedetomidine decreased nocturnal wakefulness on postoperative first day (p = 0.001). In the propofol sedation strategy, dexmedetomidine increased nocturnal deep sleep on postoperative first (p < 0.001) and third (p < 0.001) days.
CONCLUSION: Intra-operative infusion of dexmedetomidine had no significant effect on POSD but decreased nocturnal wakefulness in the sevoflurane group and increased nocturnal deep sleep in the propofol group.
TRIAL REGISTRATION: Registered at www.chictr.org.cn (ChiCTR2300070136).
This group of subjects will participate in single-task gait and balance activities for half hour and single-task cognitive training in sitting position for another half hour in each session. There will be 3 sessions per week for 8 weeks.
The anatomical features spanning from the aortic arch to the proximal carotid artery and the associated cardiovascular risks might significantly influence the development of right carotid plaque. Our research aimed to compare these anatomical and risk factors between individuals with no carotid plaque and those with moderate right-side carotid plaque within a Korean cohort. We conducted a retrospective, cross-sectional analysis involving 413 participants, categorized into a normal group (n = 339) and a right moderate carotid plaque group (defined as > 50% stenosis based on NASCET criteria) (n = 74). We collected data on cardiovascular risk factors and conducted laboratory tests. A 3D model of the carotid artery was constructed using cranio-cervical computed tomography angiography (CTA) data through semi-automated software. Measurements taken on this 3D model included the common carotid artery (CCA), internal carotid artery (ICA), external carotid artery (ECA), and carotid artery bifurcation (CAB) in terms of maximal vascular diameter, sectional area, angles of carotid bifurcation and ICA, and carotid tortuosity. When compared with the normal group, individuals in the right moderate carotid plaque group exhibited smaller angles at the carotid bifurcation, larger CCA diameter and sectional area (p < 0.01), advanced age, and a higher incidence of hypertension, diabetes, and stroke history (p < 0.05), along with reduced glomerular filtration rate (GFR) (p < 0.001). Multivariate analysis revealed that the sectional area of the bifurcation, calcification of the aortic bulb, and GFR were independently associated with the presence of right moderate carotid plaque (p < 0.01). Statistical analyses disclosed significant differences in both clinical risk factors and geometric changes in the region extending from the aortic arch to the proximal carotid artery among subjects with right moderate carotid plaque when compared to those without.
OBJECTIVE: This study aims to correlate the RAPID score with the 3-month survival and surgical results of patients undergoing lung decortication with stage III pleural empyema.
METHODS: This was a retrospective study with the population of patients with pleural empyema who underwent pulmonary decortication between January 2019 and June 2022. Data were collected from the institution's database, and patients were classified as low, medium, and high risk according to the RAPID score. The primary outcome was 3-month mortality. Secondary outcomes were the length of hospital stay, readmission rate, and the need for pleural re-intervention.
RESULTS: Of the 34 patients with pleural empyema, according to the RAPID score, patients were stratified into low risk (23.5 %), medium risk (47.1 %), and high risk (29.4 %). The high-risk group had a 3-month mortality of 40 %, while the moderate-risk group had a 6.25 % and the low-risk group had no deaths within 90 days, confirming a good correlation with the RAPID score (p < 0.05). Sensitivity and specificity for the primary outcome in the high-risk score were 80.0 % and 79.3 %, respectively. The secondary outcomes did not reach statistical significance.
CONCLUSIONS: In this retrospective series, the RAPID score had a good correlation with 3-month mortality in patients undergoing lung decortication. The morbidity indicators did not reach statistical significance. The present data justifies further studies to explore the capacity of the RAPID score to be used as a selection tool for treatment modality in patients with stage III pleural empyema.
Polyphenols, the important secondary metabolites, consist of multiple phytochemicals and show numerous physiological effects. Flavones play a significant role in various chronic disorders such as diabetes.. In this study, all the flavones were encountered, and it was further filtered based on their drug-likeness properties and pharmacokinetic parameters. Existing literature confirms that flavone-based compounds are suitable as the drug of choice in sarcopenic obesity. A molecular docking study was performed toward the myostatin inhibition profile of the flavones using PDB:3HH2 as a target site. This computer-aided drug design helps select lead molecules in novel drug discovery.
The present invention relates to a medicine for curing male impotence, which is prepared by weighing raw materials according to the following dosages: musk, ginseng, sedge grass, unhaired nux vomica, Chinese eaglewood, saffron and human placenta. The medicines are mixed and ground into powder. Honey is then taken and is heated to 70 to 80 DEGC through decoction. After decoction, when the honey is cooled to 10 to 15 DEGC, the medicinal powder is poured into the honey, uniformly stirred and made into pill. Through clinical verification, the present invention has obvious therapeutic effect on sexual hypoesthesia, spermatorrhea, heart-kidney imbalance, etc. caused by impotence, premature ejaculation, chronic nephritis, pyelitis, renal deficiency and presenility.
The present invention provides a Chinese medicinal composition which is used for stopping bleeding and eliminating scars, and a preparation method thereof, belonging to the field of Chinese medicinal composition. The Chinese medicinal composition consists of the ingredients of the following weight portions: 2 to 7 portions of Cherokee rose, 2 to 7 portions of folium mori, 2 to 7 portions of leaf of ramie anthracnose, 1 to 4 portion(s) of leaf of Chinese ilex, 1 to 4 portion(s) of buckwheat, 0.5 to 3 portion(s) of lime, 0.5 to 3 portion(s) of honey, 1 to 5 portion(s) of benne oil, 4 to 8 portions of purlin, 1 to 5 portion(s) of salt and 3 to 7 portions of aloe. The optimum ratio requires 4 portions of Cherokee rose, 4 portions of folium mori, 4 portions of leaf of ramie anthracnose, 2 portions of leaf of Chinese ilex, 2 portions of buckwheat, 1 portion of lime, 1 portion of honey, 3 portions of benne oil, 6 portions of purlin and 5 portions of aloe. The composition can be prepared in the form of powder. When in use, the composition is added into brine and then mixed to form mash; gauze is adhered on the bleeding wound or seam; the composition is coated on the gauze to effectively stop bleeding, eliminating pains or removing scars; after the wound or seam is cured, the mash and the gauze are uncovered together. The composition has the advantages of excellent curative effects, high cure rate in clinical use, wide source of raw materials, and low costs.
A method of preventing the precipitation of proteins, such as hormone preparations, within drug delivery systems that depend on the fluidity of the infusate for proper function while extending and maintaining the biological activity of the protein during its period of storage in the drug delivery system. A polyol, such as glycerol, is mixed with the protein solution prior to the introduction of the solution into the drug delivery system. The polyol isadded in amount between about 10 and 90 per cent by volume sufficient to prevent precipitation of the protein during long-term storage in the drug delivery device. A physiologically compatible buffer system in concentration between about 1 mMolar and 1000 mMolar sufficient to maintain the pH of the solution within about one unit of the optimum pH of the protein is added to maintain the bioactivity of the protein during its extended period of storage. According to one form of usage, the protein-polyol-buffer solution is injected to the pressurized drug storage reservoir of an implanted infusion pump by injection through the patient's skin. As the solution is discharged from the delivery device by the constant pressure exerted upon the storage chamber, its low rate of flow is controlled by a restricted fluid passage. The solution is conveyed to an infusion site and diluted by the blood stream.
In addition to standard rehabilitation treatment Group A will perform daily sessions of wrist robot-assisted treatment in combination with tDCS (30 minutes). During first 20 min of each session the patient receives a direct current stimulation through surface sponge electrodes (35 cm2), 2 milliampere intensity: the anodal electrode is placed on presumed lesional area, the cathodal electrode is placed on the controlateral orbital bone.
Treatment will be administered in outpatient settings. Durvalumab will be administered as infusion intravenously once every two weeks on D1 and D15, every 28 days (10 mg/Kg based on body weight) or 1500mg on D1 every 28 days. Copanlisib will be given as infusion intravenously on D1, D15 in a 28-day cycle (flat dose). The starting dose of Copalisib will be 60 mg D1 and D15. It will be reduced to 45 mg for the first dose reduction and to 30 mg for the second dose reduction. The Durvalumab dose will remain constant when Copanlisib is reduced.

Once the appropriate dose is determined, e.g. Copanlisib 60 mg iv d1, 15, q4w, in the dose-finding phase, this will become the recommended dose for the dose-expansion phase. Patients will be treated at the dose-expansion phase to increase our understanding of pharmacokinetics and to confirm safety as well as initial efficacy in this population.
To evaluate the prolonged effect of TPRMS on motor cortex excitability and help interpret and design subsequent experiments investigating the effect of TRPMS on BOLD signal. The experiment design consists of four groups, each group will include 10 participants (8 completers/group). For TRPMS stimulation sessions, our test conditions will be a 10 stimuli-session (approximately 2min), 50 stimuli-session (approximately 7min), 100 stimuli-session (approximately 14min), and 150 stimuli-session (20min) for each of the four groups, respectively. Therefore, the outcome will be measured with the spontaneous motor unit potentials (sMUPs) in the contralateral abductor pollicis brevis muscle (APB). After the stimulation session, we will measure sMUPs continuously for another 20min to observe the prolonged effect of the TRPMS stimulation and to compare these four conditions. The total approximate time required for this experiment is about 2-2.5 hours.
The present invention relates to a remote monitoring method and system for monitoring a patient suffering from a chronic inflammatory disease. The method is compatible with a system comprising a remote platform and at least one mobile user device, wherein the user device is associated with a patient and is in data communication with the platform. The method comprises a number of steps. One step is directed to receiving, at a platform, monitoring data indicative of a health condition of a patient from a user device associated with the patient. Other steps are directed to determining, at the platform, a predicted disease state of the inflammatory disease of the patient based on the received monitoring data. Other steps are aimed at evaluating the determined predicted disease state. However, other steps are also intended to provide the predicted disease state to a user at the platform and/or a patient at the user device based on the step of evaluating the determined predicted disease state. Furthermore, the present invention relates to a corresponding system for determining a predicted disease state of an inflammatory disease in a patient.
Background: Sepsis, a complex and life-threatening disease, poses a significant global burden affecting over 48 million individuals. Recently, it has been reported that programmed death-ligand 1 (PD-L1) expressed on neutrophils is involved in both inflammatory organ dysfunction and immunoparalysis in sepsis. However, there is a dearth of strategies to specifically target PD-L1 in neutrophils in vivo . Methods: We successfully developed two lipid nanoparticles (LNPs) specifically targeting neutrophils by delivering PD-L1 siRNA via neutrophil-specific antibodies and polypeptides. In vivo and in vitro experiments were performed to detect lipid nanoparticles into neutrophils. A mouse cecal ligation and puncture model was used to detect neutrophil migration, neutrophil extracellular traps level, and organ damage. Result: The PD-L1 siRNA-loaded LNPs that target neutrophils suppressed inflammation, reduced the release of neutrophil extracellular traps, and inhibited T-lymphocyte apoptosis. This approach could help maintain homeostasis of both the immune and inflammatory responses during sepsis. Furthermore, the PD-L1 siRNA-loaded LNPs targeting neutrophils have the potential to ameliorate the multiorgan damage and lethality resulting from cecal ligation and puncture. Conclusions: Taken together, our data identify a previously unknown drug delivery strategy targeting neutrophils, which represents a novel, safe, and effective approach to sepsis therapy.
Patients randomized to receive midodrine for up to 5 days in hospital at escalating doses starting at 2.5 mg po TID x 1 day, 5.0 mg po TID x 1 day, 7.5 mg po TID x 1 day, 10 mg po TID x 2 days. Patients may be discharged from hospital prior to completion of the full 5 day protocol. All patients in the midodrine treatment arm will receive otherwise usual standard of care treatments.
To identify older surgical cancer patients at risk of decreased postoperative recovery of physical activity (PA), this study assesses whether preoperative radiological sarcopenia (RS) is associated with a decreased ability to return to baseline PA. RS was defined as decreased psoas muscle mass or -density by gender-specific cut-offs on CT-scans at level of vertebra L3. PA was assessed as steps/day measured with PA tracker and recovery of PA was defined as >90% of preoperative steps/day at 3 months postoperatively. Of 44 included patients aged 65 and over undergoing oncologic surgery, 18 patients (41%) showed RS. Seventeen patients (39%) returned to baseline PA, of which eight patients had RS (47%). RS was not associated with a return to baseline PA (OR: 1.38, 95%CI 0.39-4.92, p = 0.61). In this exploratory study, no association was found between preoperative RS and recovery of PA postoperatively.
PURPOSE: A pharmaceutical composition containing Lactobacillus for treating atopic dermatitis is provided to induce the change of cytokine in the human body and to enhance the expression of interferon-gamma. CONSTITUTION: A pharmaceutical composition containing Lactobacillus for treating atopic dermatitis contains the Lactobacillus and bacteria-coated gold. The Lactobacillus is administered onto the skin and contains an active ingredient. The Lactobacillus is selected from the group consisting of Lactobacillus acidophilus La5, Bifidobacterium lactic Bb12, Streptococcus thermophiles, Lactobacillus bulgaricus, and Lactobacillus bulgaricus and oligofructose. The composition is a liquid or solid formulation. The bacteria-coated gold is obtained by culturing Lactobacillus with gold.
A process is provided for impregnating a substantial homopolymer of glycolic acid selected form substantial homopolymers of glycolic acid and block copolymers comprising at least 40 mol. % glycolic acid monomer as blocks which are substantial homopolymers of glycolic acid with a pharmaceutically active compound, the process comprising dissolving the pharmaceutically active compound in a solvent to form a solution of pharmaceutically active compound, contacting the solution with the polymer and allowing the solution to penetrate the polymer, characterised in that the solvent is liquid at atmospheric pressure and 20 °C and is capable of penetrating the polymer and is not capable of dissolving the polymer. The solvent may be for instance water or an organic solvent having solubility parameter S of from 18.5 to 28.0 Mpa1/2. The product may be used for implantation in a human or other animal subject. Also provided is a product suitable for implantation in the body of a human or other animal subject comprising a pharmaceutically active compound encapsulated by a casing which forms a barrier between the pharmaceutically active compound and the environment, wherein at least part of the barrier is formed from a membrane of glycolic acid polymer selected from substantial homopolymers of glycolic acid and block copolymers comprising at least 40 mol. % glycolic acid monomer as blocks which are substantial homopolymers of glycolic acid.
A method for administering an exposure treatment of a cognitive behavioral therapy (CBT) uses a mobile app and a server application. A user state of a patient undergoing a first step of the CBT based on the patient's condition during the first step is detected by sensors of the patient's smartphone. A situational state of the patient's surroundings during the first step is detected by the smartphone sensors. The mobile app determines whether the patient has made progress performing the first step. A user prompt is generated based on the user state and situational state. A next step of the CBT is configured based on the user state and situational state. The characteristics of the user prompt are generated using machine learning based on past task completions by the patient and other users so as to increase the likelihood that the patient will complete the next step of the CBT.
NEW MATERIAL:25-Hydroxyvitamin D3-26,23-peroxylactone expressed by the formula. USE:An orally administrable calcium adjusting agent, capable of reducing the calcium level in the blood serum, and useful for treating hypercalcemia caused by the administration of vitamin D analogs, hypercalcemia caused by malignant tumors and hypercalciuria, hyperthyroidism and Behcet's disease, etc. PROCESS:Vitamin D3 or 25-hydroxyvitamin D3 in an amount within the toxically acceptable range is administered to an animal, e.g. domestic fowl or pig, etc. by a means, e.g. oral, intravenous or intramuscular injection, etc. About 2-50hr after the administration, the compound expressed by the formula as a metabolite of the vitamin D3 or 25-hydroxyvitamin D23 is isolated and extracted from a fat-soluble portion in the blood serum of the above-mentioned animal by the column chromatography, etc.
One Intranasal spray of 14 milligram (mg) esketamine solution in each nostril on Day 1 at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 (Treatment A). Two intranasal sprays of 50 microgram (mcg) mometasone suspension in each nostril for a total dose of 200 mcg on days 1 to 15 and 2 intranasal sprays of 50 mcg mometasone suspension in each nostril for a total dose of 200 mcg at time -1 hour prior to 1 intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg on Day 16 in Period 2 (Treatment B).
PURPOSE:To obtain a solution for external use, containing oxygen in a high concentration, readily administered, having high safety for the stomach and effective in treating gastric juice diseases. CONSTITUTION:The aimed substance obtained by placing a solution composition prepared by mixing active ingredients, such as an antacid agent, with other required ingredients in a glass or plastic container, such as bottle, and blowing oxygen under a high pressure therein. The quantity of the dissolved oxygen can be increased by adding ethanol or propylene glycol. Furthermore, the quantity of the dissolved oxygen can be remarkably increased by adding a perfluorocarbon, hemoglobin, etc. A surfactant, such as glyceryl ester of a fatty acid, is preferably added to emulsify the solution composition. The oxygen is preferably contained in a larger amount than that capable of containing 30-500ppm, preferably 50-300ppm at ordinary temperature under ordinary pressure.
The invention discloses kidney-tonifying medicinal liquor with red-bone sheep bone. The kidney-tonifying medicinal liquor with red-bone sheep bone is composed of the following raw materials: red-bone sheep bone, fructus lycii, Radix Astragali, ginseng, Poria cocos, Chinese angelica, cistanche, achyranthes root, Semen Cuscutae, Serissa serissoides(DC.)Druce, Himalayan teasel root, taxillus, eucommia, Ligusticum wallichii, Radix Codonopsis, fleece-flower root, Semen Astragali Complanati, Prunella vulgaris, Cynoglossum amabile, Cordyceps sinensis, epimeddium, phellodendron, cynomorium songaricum, cortex acanthopanacis, cortex acanthopanacis, ficus pumila fruit, glutinous rehmannia, Morinda officinalis, raspberry, pyrola, Chinese gall, pilose antler, Alsophila spinulosa(Wall.ex Hook.)Tryon, liquor and rock sugar. The kidney-tonifying medicinal liquor is prepared from multiple Chinese herbal medicines for reinforcing kidney and replenishing qi, can tranquilize mind by nourishing the heart, reinforce liver and kidney and strengthen bones and muscles, has effects of reinforcing kidney and replenishing qi, tonifying Yang and enriching essence, nourishing yin for tranquillization and building up body, is pure natural, has no toxic or side effect, and has fast effectiveness. The preparation method is simple. The therapeutic method is convenient. The treatment effect is remarkable. The product is suitable for a large range of population.
<P>PROBLEM TO BE SOLVED: To provide an emulsion composition which is safe and is high in functional stability.  <P>SOLUTION: The emulsion composition is emulsified by means of a method of arranging a structural body in a first passage so as to guide a jet stream of fluid along the first passage and guide the fluid to controlled flow along a new passage, and determining the direction of the first passage and the new passage so as to generate shear force and cavitation in the fluid. The emulsion composition is constituted by compounding one kind or more of oily gelating agent, dipentaerythritol fatty acid ester and glycerol fatty acid ester adipic acid condensate. In addition, the emulsion composition is constituted by compounding one kind or more of glycyrrhizinic acid salt, hydroxy fatty acid, polyglycerol, polyethylene glycol, phenoxyethanol, 1,2 pentanediol, amino acid, peptide, protein, clay mineral, diethoxyethyl succinate, sphingoglycolipid, monoalkenyl glyceryl ether and monoalkenyl glyceryl ether. In addition, α-hydroxy acid is preferably compounded.  <P>COPYRIGHT: (C)2005,JPO&NCIPI